Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 19/20 | 0.87 |
| ▸ | TACR2 | P21452 | 2/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6449989 | 1.00 | TACR3 (0.87) | TACR3TACR2CYP3A4 | |
| Azd-7624 SCHEMBL6447341 | 0.93 | TACR3 (1.00) | TACR3TACR2 | |
| Azd-7624 SCHEMBL6447347 | 0.93 | TACR3 (1.00) | TACR3TACR2 | |
| Azd-7624 SCHEMBL6447531 | 0.93 | TACR3 (1.00) | TACR3TACR2 | |
| Azd-7624 SCHEMBL29437781 | 0.93 | TACR3 (1.00) | TACR3TACR2 | |
| SCHEMBL6448410 | 0.90 | TACR3 (0.85) | TACR3TACR2 | |
| SCHEMBL6448413 | 0.90 | TACR3 (0.85) | TACR3TACR2 | |
| SCHEMBL4464903 | 0.89 | TACR3 (0.87) | TACR3TACR2 | |
| SCHEMBL4728364 | 0.87 | TACR3 (0.84) | TACR3TACR2 | |
| SCHEMBL6450703 | 0.86 | TACR3 (0.78) | TACR3TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0940391-B1 | Quinoline derivatives as tachykinin NK3 receptor antagonists | GLAXOSMITHKLINE SPA (IT) | 2004-08-18 | — | — | EP | claimed |
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | claimed |
| US-20030236281-A1 | Quinoline derivatives(2) | FARINA CARLO (IT) | 2003-12-25 | — | — | US | claimed |
| US-6608083-B1 | Treatment and/or prophylaxis of convulsive disorders, renal disorders, urinary incontinence, ocular inflammation, eating disorders, inflammatory pain, allergic rhinitis, psoriasis,neurodegenerative disorders, Huntington's disease, | SMITHKLINE BEECHAM FARMACEUTICI S.P.A (IT) | 2003-08-19 | — | — | US | claimed |
| EP-1192952-A2 | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-04-03 | — | — | EP | claimed |
| EP-0940391-A2 | Quinoline derivatives as tachykinin NK3 receptor antagonists | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1999-09-08 | — | — | EP | claimed |
| WO-1995032948-A1 | QUINOLINE DERIVATIVES AS TACHYKININ NK3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1995-12-07 | — | — | WO | claimed |
| US-7482458-B2 | Quinoline derivatives | SMITHKLINE BEECHAM FARMACEUTICA S.P.A. (IT) | 2009-01-27 | — | — | US | disclosed |
| US-7482458-B2 | Quinoline derivatives | SMITHKLINE BEECHAM FARMACEUTICA S.P.A. (IT) | 2009-01-27 | — | — | US | disclosed |
| EP-1517708-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2004000355-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| EP-1192952-A2 | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006135-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, HTR3A | TACR3 86/4885TACR2 7/4885CYP3A4 2130/4885 |
| US-20030236281-A1 | Quinoline derivatives(2) | KCNQ3, CHRNA3, KCNK3 | TACR3 31/4885TACR2 19/4885CYP3A4 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.